אוויפלרה ישראל - עברית - Ministry of Health

אוויפלרה

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

דקוג'ן ישראל - עברית - Ministry of Health

דקוג'ן

j-c health care ltd - decitabine - אבקה להכנת תמיסה מרוכזת לעירוי - decitabine 50 mg/vial - decitabine - decitabine - - dacogen is indicated for treatment of patients with myelodysplastic syndromes (mds) including prevviously treated and untreated, de novo and secondary mds of all french-american- british subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia ) and intermediate- 1, intermediate- 2, and high-risk international prognostic scoring system groups.- dacogen is indicated for the treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary acute myeloid leukaemia (aml), according to the world health organisation (who) classification, who are not candidates for standard induction chemotherapy

זייטיגה 250 מג ישראל - עברית - Ministry of Health

זייטיגה 250 מג

j-c health care ltd - abiraterone acetate - טבליה - abiraterone acetate 250 mg - abiraterone - abiraterone - zytiga is cyp 17 inbitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer

סימפוני ישראל - עברית - Ministry of Health

סימפוני

j-c health care ltd - golimumab - תמיסה להזרקה - golimumab 50 mg / 0.5 ml - golimumab - golimumab - rheumatoid arthritis :simponi, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis when the response to disease-modifying anti-rheumatic drug (dmard) therapy including mtx has been inadequate.psoriatic arthritis :simponi, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active and progressive psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate.ankylosing spondylitis :simponi is indicated for the treatment of adult patients with severe active ankylosing spondylitis who have responded inadequately to conventional therapy.

סטלרה 45 מג ויאל ישראל - עברית - Ministry of Health

סטלרה 45 מג ויאל

j-c health care ltd - ustekinumab - תמיסה להזרקה - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - stelara™ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to,or have contraindication to or who are intolerant to other systemic therapies including ciclosporin,methotrexate and psoralen plus u.v (puva).

סטלרה מזרק מוכן לשימוש ישראל - עברית - Ministry of Health

סטלרה מזרק מוכן לשימוש

j-c health care ltd - ustekinumab - תמיסה להזרקה - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - stelara is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to, or have contraindication to or who are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen plus u.v (puva).

הלדול 5 מג ישראל - עברית - Ministry of Health

הלדול 5 מג

j-c health care ltd - haloperidol - טבליה - haloperidol 5 mg - haloperidol - haloperidol - management of manifestations of psychotic disorders. control of tics and vocal utterances of tourette's disorder.

הלדול 2 מגמל טיפות ישראל - עברית - Ministry of Health

הלדול 2 מגמל טיפות

j-c health care ltd - haloperidol - תמיסה (פומי) - haloperidol 2 mg/ml - haloperidol - haloperidol - antipsychotic, psychomotor sedative. additionally, in pediatrics, for short-term treatment of tics and vomiting (gilles de la tourettes syndrome).

הלדול דקאנואס ישראל - עברית - Ministry of Health

הלדול דקאנואס

j-c health care ltd - haloperidol as decanoate - תמיסה להזרקה - haloperidol as decanoate 100 mg/ml - haloperidol - haloperidol - maintainance therapy of chronic schizophrenic patients.

ריספרדל 1 מגמל ישראל - עברית - Ministry of Health

ריספרדל 1 מגמל

j-c health care ltd - risperidone - תמיסה - risperidone 1 mg / 1 ml - risperidone - risperidone - risperdal is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperdal was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperdal is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperdal is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperdal is indicated for the treatment of mania in bipolar disorder. these episodes are char